| Type | Title | Date Released | |
|---|---|---|---|
8-K | Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War for AP-SA02 Phase 3 Development | ||
8-K | Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02 | ||
10-Q | Form 10-Q | ||
8-K | Armata Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update | ||
8-K | Armata Pharmaceuticals Advances AP-SA02 Toward Phase 3 Clinical Trial | ||
8-K | Armata Pharmaceuticals Appoints David House as Chief Financial Officer | ||
4 | Birx Deborah (Reporting) | ||
8-K | Armata Pharmaceuticals Reaches Agreement with FDA on Pediatric Study Plan for AP-SA02 | ||
S-8 | Form S-8 | ||
8-K/A | Dr. Daniel Gilmer Appointed to Nominating and Corporate Governance Committee, Effective June 24, 2026, with Pro-rated Compensation. | ||
8-K | Armata Pharmaceuticals Receives $2.5 Million in Additional DoD Funding for AP-SA02 | ||
8-K | Armata Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Shareholders |
